Contact
Please use this form to send email to PR contact of this press release:
MedTech Stock Sigyn Therapeutics (OTC: $SIGY) Reports Results of Pilot Study to Address Inflammatory CytoVesicles
TO:
Dawn Van Zant
Investorideas.com
+ +1 800 665 0411